Orilanolimab

DB15312Investigational

Orilanolimab is under investigation in clinical trial NCT03075878 (A Safety Study of SYNT001 in Subjects With Chronic, Stable Warm Autoimmune Hemolytic Anemia (WAIHA)).

Mechanism: Pharmacologically active on IgG receptor FcRn large subunit p51
Curator reviewed
Code names: SYNT001

Resolves to

Compound

UNII1LTT6HMX9NCAS2066544-85-0

Targets

P55899FCGRT

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Orilanolimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account